Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Shore

Showing results (81-90 of 191) with videos related to

Pageof 20
Sort By:
Journal of Comparative Effectiveness Research|January 6, 2026
Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancerNeal Shore, Alicia K Morgans, Noman Paracha, et al.
Advances in Therapy|June 17, 2025
Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerMehmet A Bilen, Sabree Burbage, Carmine Rossi, et al.
Urologic Oncology|March 19, 2021
Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuationAnne M Rentz, Sonal G Mansukhani, Jinan Liu, et al.
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
The Journal of Urology|May 16, 2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder CancerMax Kates, Ahmed M Mansour, Donald L Lamm, et al.
European Urology|December 8, 2009
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristicsBertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, et al.
Urology|April 8, 2019
Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United StatesJeremy B Shelton, Phil Buffington, Richard Augspurger, et al.
Targeted Oncology|April 15, 2023
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate CancerJose De La Cerda, Curtis Dunshee, Lawrence Gervasi, et al.
Urology|January 31, 2026
Homologous recombination repair mutations, next-generation sequencing testing, and treatment progression by race among patients with metastatic castration-sensitive prostate cancerMehmet A Bilen, Neal Shore, Sabree Burbage, et al.
Pageof 20

Showing results (81-90 of 191) with videos related to

Sort By:
Pageof 20
Journal of Comparative Effectiveness Research|January 6, 2026
Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancerNeal Shore, Alicia K Morgans, Noman Paracha, et al.
Advances in Therapy|June 17, 2025
Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerMehmet A Bilen, Sabree Burbage, Carmine Rossi, et al.
Urologic Oncology|March 19, 2021
Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuationAnne M Rentz, Sonal G Mansukhani, Jinan Liu, et al.
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
The Journal of Urology|May 16, 2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder CancerMax Kates, Ahmed M Mansour, Donald L Lamm, et al.
European Urology|December 8, 2009
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristicsBertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, et al.
Urology|April 8, 2019
Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United StatesJeremy B Shelton, Phil Buffington, Richard Augspurger, et al.
Targeted Oncology|April 15, 2023
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate CancerJose De La Cerda, Curtis Dunshee, Lawrence Gervasi, et al.
Urology|January 31, 2026
Homologous recombination repair mutations, next-generation sequencing testing, and treatment progression by race among patients with metastatic castration-sensitive prostate cancerMehmet A Bilen, Neal Shore, Sabree Burbage, et al.
Pageof 20